Your browser doesn't support javascript.
loading
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection.
Alexandre, Marie; Marlin, Romain; Prague, Mélanie; Coleon, Severin; Kahlaoui, Nidhal; Cardinaud, Sylvain; Naninck, Thibaut; Delache, Benoit; Surenaud, Mathieu; Galhaut, Mathilde; Dereuddre-Bosquet, Nathalie; Cavarelli, Mariangela; Maisonnasse, Pauline; Centlivre, Mireille; Lacabaratz, Christine; Wiedemann, Aurelie; Zurawski, Sandra; Zurawski, Gerard; Schwartz, Olivier; Sanders, Rogier W; Le Grand, Roger; Levy, Yves; Thiébaut, Rodolphe.
Afiliación
  • Alexandre M; University of Bordeaux, Department of Public Health, Inserm Bordeaux Population Health Research Centre, Inria SISTM, Bordeaux, France.
  • Marlin R; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Prague M; University of Bordeaux, Department of Public Health, Inserm Bordeaux Population Health Research Centre, Inria SISTM, Bordeaux, France.
  • Coleon S; Vaccine Research Institute, Créteil, France.
  • Kahlaoui N; Inserm U955, Créteil, France.
  • Cardinaud S; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Naninck T; Vaccine Research Institute, Créteil, France.
  • Delache B; Inserm U955, Créteil, France.
  • Surenaud M; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Galhaut M; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Dereuddre-Bosquet N; Vaccine Research Institute, Créteil, France.
  • Cavarelli M; Inserm U955, Créteil, France.
  • Maisonnasse P; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Centlivre M; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Lacabaratz C; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Wiedemann A; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, Fontenay-aux-Roses, France.
  • Zurawski S; Vaccine Research Institute, Créteil, France.
  • Zurawski G; Inserm U955, Créteil, France.
  • Schwartz O; Vaccine Research Institute, Créteil, France.
  • Sanders RW; Inserm U955, Créteil, France.
  • Le Grand R; Vaccine Research Institute, Créteil, France.
  • Levy Y; Inserm U955, Créteil, France.
  • Thiébaut R; Baylor Scott and White Research Institute, Dallas, United States.
Elife ; 112022 07 08.
Article en En | MEDLINE | ID: mdl-35801637
ABSTRACT
The definition of correlates of protection is critical for the development of next-generation SARS-CoV-2 vaccine platforms. Here, we propose a model-based approach for identifying mechanistic correlates of protection based on mathematical modelling of viral dynamics and data mining of immunological markers. The application to three different studies in non-human primates evaluating SARS-CoV-2 vaccines based on CD40-targeting, two-component spike nanoparticle and mRNA 1273 identifies and quantifies two main mechanisms that are a decrease of rate of cell infection and an increase in clearance of infected cells. Inhibition of RBD binding to ACE2 appears to be a robust mechanistic correlate of protection across the three vaccine platforms although not capturing the whole biological vaccine effect. The model shows that RBD/ACE2 binding inhibition represents a strong mechanism of protection which required significant reduction in blocking potency to effectively compromise the control of viral replication.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Animals / Humans Idioma: En Año: 2022 Tipo del documento: Article